Chemistry:CU-13001

From HandWiki

CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease.[1][2][3][4][5] It is taken orally.[1] It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease.[3][4] The drug is under development by Acurex Biosciences.[1][2][4] As of September 2024, it is in the preclinical research stage of development for Parkinson's disease.[1][2][5][4] The chemical structure of CU-13001 does not yet appear to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "CU 13001". 28 September 2024. https://adisinsight.springer.com/drugs/800079064. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on CU-13001 with Synapse". 30 May 2026. https://synapse.patsnap.com/drug/57c6a479a4f04a7f9f816f2997897fdf. 
  3. ↑ 3.0 3.1 "Parkinson disease is a fatty acidopathy". Nature Reviews. Neurology 21 (11): 642–655. November 2025. doi:10.1038/s41582-025-01142-2. PMID 41034503. "The biological effects of some PUFAs might be elicited through their oxidation products, for example, oxylipins55. Targeting of such signalling molecules and byproducts of fatty acid metabolism might have therapeutic promise. One example under consideration in preclinical studies is reduction of a PUFA peroxidation product, 4-hydroxynonenal (4-HNE), using an inhibitor (CU-13001) of 15-lipoxygenase (15- LO).". 
  4. ↑ 4.0 4.1 4.2 4.3 Parkinson's UK (7 August 2024). "Parkinson's UK invests in developing potential new drug with Acurex Biosciences". Parkinson's UK. https://www.parkinsons.org.uk/news/2024/parkinsons-uk-invests-developing-potential-new-drug-acurex-biosciences. 
  5. ↑ 5.0 5.1 "Preclinical Efficacy Studies for CU-13001, a 15-Lipoxygenase Inhibitor for the Treatment of Parkinson's Disease". https://www.michaeljfox.org/grant/preclinical-efficacy-studies-cu-13001-15-lipoxygenase-inhibitor-treatment-parkinsons-disease. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CU-13001&oldid=4531590"